Identification
- Summary
Guaifenesin is an expectorant commonly found in OTC products for the symptomatic relief from congested chests and coughs associated with cold, bronchitis, and/or other breathing illnesses.
- Brand Names
- Broncotron, Bronkaid, Cheracol D, Cheratussin, Cheratussin Dac, Codar Gf, Coricidin Hbp Chest Congestion, DM, Deconex, Delsym Cough Plus Chest Congestion DM, Despec Reformulated Jun 2008, Diabetic Tussin DM, Diabetic Tussin EX, Diphen, Entex Lq, Entex T, G-zyncof, Gilphex, M-clear Wc, Mar-cof Cg, Mucinex, Mucinex Children's Cough, Mucinex Cough, Mucinex D, Mucinex DM, Ninjacof Xg, Obredon, Pediacare Children's Cough and Congestion, Refenesen, Refenesen PE, Rescon-GG, Robafen, Robafen DM, Robitussin Chest Congestion, Robitussin Cough & Congestion, Robitussin Maximum Strength Cough Plus Chest Congestion DM, Safetussin DM, Scot-tussin, Scot-tussin DM, Siltussin, Tusnel C, Tusnel Diabetic
- Generic Name
- Guaifenesin
- DrugBank Accession Number
- DB00874
- Background
Guaifenesin possesses a storied history, having been originally formally approved by the US FDA in 1952 and continues to be one of very few - if not perhaps the only drug that is readily available and used as an expectorant 11. Since that time the agent has been a combination component of various prescription and non-prescription over-the-counter cough and cold products and is currently a widely available over-the-counter generic medication 11. Although it is principally believed that guaifenesin elicits an action to facilitate productive cough to manage chest congestion 4,7,9,10,11, it is not known whether the agent can reliably mitigate coughing.
Regardless, on March 1, 2007, the FDA received a petition asking the FDA to notify the public that some antitussives, expectorants, decongestants, antihistamines, and cough/cold combinations are not known to be safe and effective in children under the age of 6 years 11. After the negotiation between FDA and major manufacturers, a voluntary transition of labels for not using guaifenesin in children under the age of 4 years was endorsed by FDA in 2008 11.
Furthermore, there has also been contemporary research to suggest that guaifenesin possesses and is capable of demonstrating anticonvulsant and muscle relaxant effects to some degree possibly by acting as an NMDA receptor antagonist 3.
- Type
- Small Molecule
- Groups
- Approved, Investigational, Vet approved
- Structure
Structure for Guaifenesin (DB00874)
- Weight
- Average: 198.2158
Monoisotopic: 198.089208936 - Chemical Formula
- C10H14O4
- Synonyms
- Glyceryl guaiacolate
- Guaifenesin
- Guaifenesina
- guaiphenesin
Pharmacology
- Indication
Guaifenesin is an expectorant that is indicated for providing temporary symptomatic relief from congested chests and coughs which may be due to a cold, bronchitis, and/or other breathing illnesses Label,8,6.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Allergic reactions Combination Product in combination with: Chlorpheniramine (DB01114) •••••••••••• ••••• Used in combination to manage Asthma Combination Product in combination with: Theophylline (DB00277) •••••••••••• Used in combination to treat Asthma, allergic Combination Product in combination with: Chlorpheniramine (DB01114) •••••••••••• ••••• Used in combination for symptomatic treatment of Bronchial asthma Combination Product in combination with: Ephedrine (DB01364) •••••••••••• ••••• Used in combination to manage Bronchitis Combination Product in combination with: Theophylline (DB00277) •••••••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Guaifenesin is categorized as an expectorant that acts by enhancing the output of phlegm (sputum) and bronchial secretions via decreasing the adhesiveness and surface tension of such material 9. Furthermore, guaifenesin elicits an increased flow of less viscous gastric secretions that subsequently promote ciliary action - all actions that ultimately change dry, unproductive coughing to coughs that are more productive and less frequent 9. Essentially, by decreasing the viscosity and adhesiveness of such secretions, guaifenesin enhances the efficacy of mucociliary activity in removing accumulated secretions from the upper and lower airway 9.
- Mechanism of action
Although the exact mechanism of action of guaifenesin may not yet be formally or totally elucidated, it is believed that expectorants like guaifenesin function by increasing mucus secretion 4. Moreover, it is also further proposed that such expectorants may also act as an irritant to gastric vagal receptors, and recruit efferent parasympathetic reflexes that can elicit glandular exocytosis that is comprised of a less viscous mucus mixture 4. Subsequently, these actions may provoke coughing that can ultimately flush difficult to access, congealed mucopurulent material from obstructed small airways to facilitate a temporary improvement for the individual 4.
Consequently, while it is generally proposed that guaifenesin functions as an expectorant by helping to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive, there has also been research to suggest that guaifenesin possesses and is capable of demonstrating anticonvulsant and muscle relaxant effects to some degree possibly by acting as an NMDA receptor antagonist 3.
Target Actions Organism UNMDA receptor antagonistHumans - Absorption
Studies have shown that guaifenesin is well absorbed from and along the gastrointestinal tract after oral administration 2,10,7.
- Volume of distribution
The geometric mean apparent volume of distribution of guaifenesin determined in healthy adult subjects is 116L (CV=45.7%) 11.
- Protein binding
Information regarding the protein binding of guaifenesin is not readily available or accessible.
- Metabolism
After the oral administration of 400 mg guaifenesin, the agent experiences rapid hydrolysis (more than 60% of the dose hydrolyzed over a range of seven hours) with β-(2-methoxyphenoxy)-lactic acid found as the major urinary metabolite but no parent drug detectable in the urine 5,7. Moreover, it has been observed that guaifenesin also experiences both oxidation and demethylation 5. In particular, the medication is quickly metabolized hepatically by way of oxidation to β-(2-methoxyphenoxy)-lactic acid 5. Furthermore, guaifenesin is also demethylated by O-demethylase in liver microsomes to the point where about 40% of an administered dose is excreted as this metabolite in the urine within 3 hours 5. In fact, O-demethylase appears to be the primary enzyme for the metabolism of guaifenesin and the primary metabolites of the substance are β-(2-methoxyphenoxy)-lactic acid and the demethylated hydroxyguaifenesin, both of which are themselves inactive moieties 5.
Hover over products below to view reaction partners
- Route of elimination
After administration, guaifenesin is metabolized and then largely excreted in the urine 5,6,7,10,11.
- Half-life
The half-life in plasma observed for guaifenesin is approximately one hour 5,6,7,10,11.
- Clearance
The mean clearance recorded for guaifenesin is about 94.8 L/hr (CV=51.4%) 11.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The most prevalent signs and symptoms associated with an overdose of guaifenesin have been nausea and vomiting 7.
Although adequate and well-controlled studies in pregnant women have not been performed, the Collaborative Perinatal Project monitored 197 mother-child pairs exposed to guaifenesin during the first trimester 7. An increased occurrence of inguinal hernias was found in the neonates 7. However, congenital defects were not strongly associated with guaifenesin use during pregnancy in 2 large groups of mother-child pairs 7.
Moreover, guaifenesin is excreted in breast milk in small quantities 7. Subsequently, caution should be exercised by balancing the potential benefit of treatment against any possible risks 7.
Additionally, an LD50 value of 1510 mg/kg (rat, oral) has been reported for guaifenesin MSDS.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Take with a full glass of water.
- Take with or without food. The absorption is unaffected by food.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Images
- International/Other Brands
- Duratuss G / Ganidin (Cypress) / Hustosil (Kyoto Yakuhin) / Hytuss (Hyrex) / Robitussin (Wyeth) / Scot-tussin Expectorant / Sinumist-SR
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Guaifenesin Tablet 600 mg/1 Oral Prasco, Laboratories 2010-12-01 2011-01-20 US 
Guaifenesin Tablet 1200 mg/1 Oral Prasco, Laboratories 2010-12-01 2011-01-20 US Guaifenesin Tablet 200 mg/1 Oral Contract Pharmacy Services Pa 2010-10-06 Not applicable US Guaifenesin Tablet 1000 mg/1 Oral Prasco, Laboratories 2010-12-01 2011-01-20 US Guaifenesin Nr Liquid 100 mg/5mL Oral Silarx Pharmaceuticals, Inc. 2000-02-01 2011-02-04 US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image 12 Hour Mucus Relief Tablet, extended release 600 mg/1 Oral CHAIN DRUG MARKETING ASSOCIATION INC 2021-09-17 Not applicable US 7 Select Mucus Relief Tablet, extended release 600 mg/1 Oral 7 Eleven 2014-10-26 2017-06-07 US Adult Tussin Syrup 100 mg/5mL Oral Rite Aid 2013-09-21 2015-10-15 US Adult Tussin Chest Congestion Solution 200 mg/10mL Oral Walgreen Company 2022-06-07 Not applicable US Adult Tussin Chest Congestion Solution 200 mg/10mL Oral HYVEE INC 1997-06-25 2019-08-05 US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 24/7 Life Cold and Flu DayTime Severe Guaifenesin (200 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide monohydrate (10 mg/1) + Phenylephrine hydrochloride (5 mg/1) Tablet, film coated Oral Lil' Drug Store Products, Inc. 2021-10-27 Not applicable US 7 Select Maximum Strength Guaifenesin (400 mg/20mL) + Dextromethorphan hydrobromide monohydrate (20 mg/20mL) Solution Oral 7-Eleven 2019-03-25 Not applicable US 7 select Tussin DM Guaifenesin (200 mg/10mL) + Dextromethorphan hydrobromide monohydrate (20 mg/10mL) Solution Oral 7-Eleven 2016-05-31 2021-06-30 US Acetaflu Cough and Chest Congestion Guaifenesin (400 mg/5g) + Dextromethorphan hydrobromide monohydrate (20 mg/5g) Powder Oral Advanced Pharmaceutical Services, Inc. Dba Affordable Quality Pharmaceuticals 2020-08-31 Not applicable US Acetaminophen 500mg, Dextromethorphan HBr 10mg, Guaifenesin 200mg, Phenylephrine HCl 5mg Guaifenesin (200 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide monohydrate (10 mg/1) + Phenylephrine hydrochloride (5 mg/1) Tablet Oral Strive Pharmaceuticals Inc 2018-12-20 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image A-Tan 12X Suspension Guaifenesin (100 mg/5mL) + Mepyramine tannate (30 mg/5mL) + Phenylephrine tannate (5 mg/5mL) Suspension Oral Amneal Pharmaceuticals 2006-01-06 2008-12-05 US Aquanaz Guaifenesin (400 mg/1) + Dextromethorphan hydrobromide monohydrate (15 mg/1) + Phenylephrine hydrochloride (10 mg/1) Tablet Oral Capital Pharmaceutical, LLC 2015-03-10 Not applicable US Bromhist PDX Guaifenesin (50 mg/5mL) + Brompheniramine maleate (2 mg/5mL) + Dextromethorphan hydrobromide monohydrate (5 mg/5mL) + Phenylephrine hydrochloride (5 mg/5mL) Syrup Oral Cypress Pharmaceutical, Inc 2006-04-28 2011-08-26 US Brontuss Guaifenesin (400 mg/1) + Dextromethorphan hydrobromide monohydrate (20 mg/1) Tablet Oral Portal Pharmaceuticals 2010-05-03 2012-05-31 US Carbatuss Guaifenesin (100 mg/5mL) + Pentoxyverine citrate (20 mg/5mL) + Phenylephrine hydrochloride (10 mg/5mL) Liquid Oral Gm Pharmaceuticals 2000-11-01 2007-11-01 US
Categories
- ATC Codes
- R05CA03 — Guaifenesin
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Phenol ethers
- Sub Class
- Anisoles
- Direct Parent
- Anisoles
- Alternative Parents
- Phenoxy compounds / Methoxybenzenes / Alkyl aryl ethers / Secondary alcohols / 1,2-diols / Primary alcohols / Hydrocarbon derivatives
- Substituents
- 1,2-diol / Alcohol / Alkyl aryl ether / Anisole / Aromatic homomonocyclic compound / Ether / Hydrocarbon derivative / Methoxybenzene / Monocyclic benzene moiety / Organic oxygen compound
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 495W7451VQ
- CAS number
- 93-14-1
- InChI Key
- HSRJKNPTNIJEKV-UHFFFAOYSA-N
- InChI
- InChI=1S/C10H14O4/c1-13-9-4-2-3-5-10(9)14-7-8(12)6-11/h2-5,8,11-12H,6-7H2,1H3
- IUPAC Name
- 3-(2-methoxyphenoxy)propane-1,2-diol
- SMILES
- COC1=CC=CC=C1OCC(O)CO
References
- Synthesis Reference
Wilfred P. Shum, Harry Mazurek, Jian Chen, "Process for producing enantiomerically enriched guaifenesin." U.S. Patent US5495052, issued August, 1949.
US5495052- General References
- Thompson GA, Solomon G, Albrecht HH, Reitberg DP, Guenin E: Guaifenesin Pharmacokinetics Following Single-Dose Oral Administration in Children Aged 2 to 17 Years. J Clin Pharmacol. 2016 Jul;56(7):894-901. doi: 10.1002/jcph.682. Epub 2016 Jan 24. [Article]
- Kagan L, Lavy E, Hoffman A: Effect of mode of administration on guaifenesin pharmacokinetics and expectorant action in the rat model. Pulm Pharmacol Ther. 2009 Jun;22(3):260-5. doi: 10.1016/j.pupt.2008.12.020. Epub 2009 Jan 6. [Article]
- Keshavarz M, Showraki A, Emamghoreishi M: Anticonvulsant Effect of Guaifenesin against Pentylenetetrazol-Induced Seizure in Mice. Iran J Med Sci. 2013 Jun;38(2):116-21. [Article]
- Yuta A, Baraniuk JN: Therapeutic approaches to mucus hypersecretion. Curr Allergy Asthma Rep. 2005 May;5(3):243-51. [Article]
- Albrecht HH, Dicpinigaitis PV, Guenin EP: Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections. Multidiscip Respir Med. 2017 Dec 11;12:31. doi: 10.1186/s40248-017-0113-4. eCollection 2017. [Article]
- MyHealth.Alberta.ca Network: Guaifenesin - Oral Profile [Link]
- Electronic Medicines Compendium: Robitussin Chesty Cough Medicine Monograph [Link]
- Australian Government Department of Health Therapeutic Goods Administration OTC Medicines Monograph: Guaifenesin [File]
- A NOVEL STABILITY INDICATING HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF GUAIPHENESIN, CHLORPHENERAMINE MALEATE & DEXTROMETHORPHAN HBr [File]
- National Pharmaceutical Regulatory Agency (NPRA) Guaiphenesin Product Information [File]
- CENTER FOR DRUG EVALUATION AND RESEARCH: CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) OF GUAIFENESIN/HYDROCODONE BITARTRATE [File]
- External Links
- Human Metabolome Database
- HMDB0004998
- KEGG Drug
- D00337
- PubChem Compound
- 3516
- PubChem Substance
- 46508004
- ChemSpider
- 3396
- BindingDB
- 50240098
- 5032
- ChEBI
- 5551
- ChEMBL
- CHEMBL980
- PharmGKB
- PA449818
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Guaifenesin
- FDA label
- Download (394 KB)
- MSDS
- Download (73.4 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Basic Science Healthy Subjects (HS) 1 4 Completed Other CYP2D6 Polymorphism 1 4 Completed Prevention Acute Upper Respiratory Track Infection 1 4 Completed Treatment Acute Respiratory Infections (ARIs) / Acute rhino-sinusitis 1 4 Completed Treatment Acute Respiratory Infections (ARIs) / Bronchitis / Rhino Sinusitis 1
Pharmacoeconomics
- Manufacturers
- Reckitt benckiser inc
- Packagers
- Adams Labs
- Advanced Pharmaceutical Services Inc.
- Alba Pharmacal
- Aligon Pharmaceuticals Inc.
- Allegis Pharmaceuticals
- Ambi Pharmaceuticals Inc.
- Amend
- Amerisource Health Services Corp.
- Anip Acquisition Co.
- A-S Medication Solutions LLC
- Atlantic Biologicals Corporation
- Baroli
- Bayer Healthcare
- Bio Pharm Inc.
- Boca Pharmacal
- Bradley Pharmaceuticals Inc.
- Breckenridge Pharmaceuticals
- Brighton Pharmaceuticals
- Bryant Ranch Prepack
- BTA Pharmaceuticals
- Capellon Pharmaceuticals LLC
- Caraco Pharmaceutical Labs
- Cardinal Health
- Carwin Associates Inc.
- Centurion Labs
- Century Pharmaceuticals Inc.
- Chemins Co. Inc.
- Co Med Pharmaceuticals Inc.
- Contract Pharm
- CVS Pharmacy
- Cypress Pharmaceutical Inc.
- Dartmouth Pharmaceuticals Inc.
- Deliz Pharmaceutical Corp.
- Deltex Pharmaceuticals Inc.
- Dental Essentials Inc.
- Deston Therapeutics
- Direct Dispensing Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Duramed
- Econolab Inc.
- Elge Inc.
- Emrex Economed Pharmaceuticals Inc.
- Ethex Corp.
- Everett Laboratories Inc.
- Generics Puerto Rico Inc.
- Gm Pharmaceuticals Inc.
- Great Southern Laboratories
- Hawthorn Pharmaceuticals
- Health Care Products
- Heartland Repack Services LLC
- Hi Tech Pharmacal Co. Inc.
- Iopharm Laboratories Inc.
- Ivax Pharmaceuticals
- Jaymac Pharmaceuticals LLC
- Kaiser Foundation Hospital
- Kiel Laboratories Inc.
- KV Pharmaceutical Co.
- Kylemore Pharmaceuticals
- Lark Pharmaceuticals Inc.
- Larken Laboratories Inc.
- Liberty Pharmaceuticals
- Llorens Pharmaceutical
- Major Pharmaceuticals
- Marnel Pharmaceuticals Inc.
- MCR American Pharmaceuticals Inc.
- Meda AB
- Murfreesboro Pharmaceutical Nursing Supply
- Neilgen Pharma Inc.
- Nexgen Pharma Inc.
- Norega Laboratories Inc.
- Nucare Pharmaceuticals Inc.
- Pack Pharmaceuticals
- Palmetto Pharmaceuticals Inc.
- Pamlab LLC
- Patheon Inc.
- PCA LLC
- PD-Rx Pharmaceuticals Inc.
- Pegasus Laboratories Inc.
- Pharma Medica Research Inc.
- Pharmaceutical Association
- Pharmaceutical Packaging Center
- Pharmaceutical Utilization Management Program VA Inc.
- Pharmedix
- Physicians Total Care Inc.
- Poly Pharmaceuticals Inc.
- Portal Inc.
- Prasco Labs
- PRD Health Care
- Preferred Pharmaceuticals Inc.
- Prepak Systems Inc.
- Provident Pharmaceuticals LLC
- Qualitest
- Quality Care
- RA McNeil Co.
- Rebel Distributors Corp.
- Reckitt Benckiser Inc.
- Remedy Repack
- Resource Optimization and Innovation LLC
- Respa Pharmaceuticals Inc.
- Rij Pharmaceutical Corp.
- River's Edge Pharmaceuticals
- Sage Pharmaceuticals Inc.
- Savage Labs
- Scientific Laboratories Inc.
- Scot-Tussin Lab
- Seatrace Pharmaceuticals Inc.
- Select Brand
- Seyer Pharmatec Inc.
- Silarx Pharmaceuticals
- SJ Pharmaceuticals LLC
- Southwood Pharmaceuticals
- Stewart Jackson Pharmacal Inc.
- Superior Pharmeceuticals
- Teamm Pharmaceuticals Inc.
- Teral Laboratories
- Teva Pharmaceutical Industries Ltd.
- TG United Inc.
- Tri Med Laboratories Inc.
- Unigen Pharmaceuticals
- United Research Laboratories Inc.
- Vindex Pharmaceuticals Inc.
- Vintage Pharmaceuticals Inc.
- Walgreen Co.
- Weeks & Leo Co.
- Wockhardt Ltd.
- Wyeth Pharmaceuticals
- Zyber Pharmaceuticals
- Dosage Forms
Form Route Strength Syrup Oral 1.330 g Powder Oral Solution Oral Liquid Topical Liquid Topical 100 mg/5mL Solution Oral 6 mg/5ml Tablet, effervescent Oral Suspension / drops Oral Liquid Oral Solution Oral 100 mg/5ml Tablet, orally disintegrating Oral Lozenge Oral Syrup Oral 1.9 % Tablet, coated Oral Tablet, multilayer Oral Liquid Oral 100 mg/5mL Liquid Oral 100 mg / 5 mL Solution Oral 100 mg/5mL Solution Oral 200 mg/5mL Solution Oral Kit; solution Oral Solution Oral 2.500 g Capsule Oral 15 MG Capsule, extended release Oral 30 mg Powder Not applicable 95 mg/100mg Capsule, gelatin coated; kit; tablet Oral Capsule, liquid filled Oral Suppository Rectal Kit; tablet; tablet, coated Oral Kit; liquid Oral Capsule; kit Oral Capsule Oral Tablet Oral 600.000 mg Capsule Liquid Oral 200 mg/5mL Syrup Not applicable Cream; kit; liquid; ointment; tablet; tablet, chewable; tablet, film coated Oral; Topical Kit Oral Tablet, multilayer, extended release Oral Tablet Oral 100 mg/1 Granule Oral Syrup Oral 100 mg / 5 mL Liquid Oral 200 mg / 5 mL Capsule Oral Solution / drops Nasal Solution Oral 400 mg/10mL Syrup Oral 2000 mg Tablet, film coated Oral Syrup Oral 200 mg/10mL Syrup Oral 200000 g Solution / drops Oral 100 mg/g Syrup Oral 20 mg/ml Powder Not applicable 1 kg/1kg Solution Oral 300 mg/15mL Tablet Oral Tablet Oral 1000 mg/1 Tablet Oral 1200 mg/1 Tablet Oral 200 mg/1 Tablet Oral 50 MG Tablet Oral 600 mg/1 Tablet, extended release Oral 1200 mg/1 Syrup Oral 1 g Solution Oral 2 g Syrup Oral 2 g Syrup Oral 100 mg/5mL Elixir Oral Syrup Oral 100 mg / 10 mL Gel Oral Syrup Oral 1.6 g Tablet, orally disintegrating Oral 100 mg/1 Syrup Oral 20 mg / mL Liquid Oral 20 mg / mL Tablet Solution Intramuscular 200.000 mg Liquid Oral 5 g/100mL Syrup Oral 50 mg/5mL Granule Oral 100 mg/1 Kit; tablet Oral Tablet, delayed release Oral 600 mg Tablet, extended release Oral 600 mg/1 Tablet, multilayer, extended release Oral 600 mg Kit; solution; suspension Oral Tablet, extended release Oral Tablet, multilayer, extended release Oral 1200 mg Tablet, extended release Oral 600 MG Kit; tablet, film coated Oral Solution Oral 400 mg/20mL Powder, for solution Oral Granule Oral 50 mg/1 Kit; tablet, coated; tablet, film coated Oral Capsule, liquid filled; kit; solution Nasal; Oral Syrup Oral 5 mg/5ml Solution Oral 100 mg / 5 mL Tablet, multilayer, extended release Oral 600 mg/1 Tablet, coated Oral 400 mg/1 Tablet, film coated Oral 400 mg/1 Tablet, multilayer, extended release Oral 1200 mg/1 Solution Oral 12.5 mg/5ml Capsule, coated Oral Tablet Oral 150 MG/10MG Liquid Oral Suspension Solution Oral 80 mg/5ml Tablet Oral Syrup Oral Syrup Oral 200 mg/5mL Tablet Oral 400 mg/1 Syrup Oral 200 mg / 5 mL Syrup Oral 8 mg/10ml Liquid Oral 200 mg/10mL Syrup Oral 100 mg/5ml Kit; powder, for solution Oral Tablet Oral 750 mg/1 Kit; tablet, coated Oral Tablet, film coated Oral 150 mg Solution Oral 200 mg/10mL Syrup Oral 1.500 g Capsule, gelatin coated Oral Solution / drops Oral Syrup Oral 1.33 g Liquid Oral 100 mg/6.25mL Syrup Oral 200 mg / 15 mL Liquid Oral 200 mg/15mL Liquid Oral 200 mg / 15 mL Capsule, liquid filled; kit Oral Syrup Oral 200 mg/15ml Syrup Oral Liquid Oral 50 mg/5ml Suspension Oral Tablet Oral 100 mg Tablet, sugar coated Oral Syrup Nasal Elixir Tablet Respiratory (inhalation) Tablet Oral 400 mg Tablet Oral 200 mg Solution Syrup Tablet, film coated - Prices
Unit description Cost Unit Diabetic Tussin Max St 10-200 mg/5ml Liquid 118ml Bottle 15.99USD bottle Naldecon Senior EX 200 mg/5ml Syrup 118ml Bottle 15.99USD bottle P-ephed w/guaifen tablet 1.21USD tablet P-ephedrine-guaifen la tablet 1.14USD tablet Guaifen/p-ephed tablet sa 1.01USD tablet Organidin nr 200 mg tablet 0.89USD tablet Mucinex dm er 1200-60 mg tablet 0.8USD tablet Pseudoephedrine-guaifen tr tablet 0.76USD tablet Humibid e 400 mg tablet 0.74USD tablet Mucinex d er tablet 0.73USD tablet P-ephed w/guaifen tablet sr 0.67USD tablet Pseudoephedrine-guaif sr tablet 0.63USD tablet Guaifenesin/p-ephedrine tablet 0.62USD tablet P-ephed-guaifen tablet la 0.6USD tablet Kid's mucinex mini-melts pack 0.57USD each Mucinex cough mini-melt pack 0.57USD each Mucinex d tablet 0.54USD tablet Organidin NR 100 mg/5ml Liquid 0.49USD ml Codeine 10 mg-guai 300 mg liq 0.46USD ml Mucinex er 600 mg tablet 0.44USD tablet Mucinex 600 mg tablet 0.42USD tablet Mucinex full force nasal spray 0.42USD ml Mucinex moisture smart nas spr 0.42USD ml Tussi-Organidin NR 300-10 mg/5ml Liquid 0.39USD ml Mucus relief 400 mg tablet 0.37USD tablet Codeine-guaifen 10 mg-200 mg liq 0.28USD ml Guaifenesin 200 mg tablet 0.28USD tablet Guaifenesin-dm 400-20 mg tablet 0.25USD tablet Robitussin coughgels 0.25USD each Diabetic tussin ex 400 tablet 0.2USD tablet G-fenesin dm 20-400 mg caplet 0.2USD caplet Organ-i nr 200 mg tablet 0.2USD tablet G-fenesin 400 mg caplet 0.19USD caplet Guaifenesin 400 mg tablet 0.16USD tablet Chest congestion relief tablet 0.15USD tablet Guaifen p-ephed caplet er 0.15USD caplet Fenesin dm ir tablet 0.13USD tablet Fenesin pe ir tablet 0.13USD tablet Guaifenesin nr liquid 0.13USD ml Fenesin ir 400 mg tablet 0.1USD tablet Guaifenesin-dm nr liquid 0.1USD ml Guaifenesin-DM 100-10 mg/5ml Liquid 0.09USD ml Robitussin dm to go liquid 0.09USD ml Guaiacol liquid purified 0.08USD ml Guaifenesin dac oral solution 0.08USD ml Guaifenesin nr 100 mg/5 ml 0.08USD ml Children's mucinex cough liq 0.06USD ml Mucinex cold liquid 0.06USD ml Naldecon-dx senior 0.06USD ml Child's mucinex 100 mg/5 ml lq 0.05USD ml Guiatuss-dm syrup 0.05USD ml Adlt robitussin cough-cold-flu 0.04USD ml Adt robitussin cough-cold d lq 0.04USD ml Adult robitussin cough syrup 0.04USD ml Guiatuss DAC 30-10-100 mg/5ml Solution 0.04USD ml Robitussin chest congest syrup 0.04USD ml Robitussin cough & cold liquid 0.04USD ml Robitussin cough-cold liquid 0.04USD ml Robitussin cough-cong syrup 0.04USD ml Robitussin dm max liquid 0.04USD ml Robitussin long-acting liq 0.04USD ml Robitussin pe head & chest liq 0.04USD ml Robitussin-cough-chest-cong lq 0.04USD ml Robitussin-dm cough syrup 0.04USD ml Scot-tussin 100 mg/5 ml liq 0.04USD ml Guiatuss ac syrup 0.03USD ml Guiatuss-dac syrup 0.03USD ml Sb cough control syrup 0.03USD ml Guaifenesin ac cough syrup 0.02USD ml Guaifenesin dm syrup 0.02USD ml Guiatuss dm syrup 0.02USD ml Guiatuss-pe syrup 0.02USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US6372252 No 2002-04-16 2020-04-28 US US6955821 No 2005-10-18 2020-04-28 US US7838032 No 2010-11-23 2020-04-28 US US9549907 No 2017-01-24 2035-11-13 US US9808431 No 2017-11-07 2035-11-13 US US10105324 No 2018-10-23 2035-11-13 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 78.5-79 British Patent 628,497. boiling point (°C) 215 °C at 1.90E+01 mm Hg PhysProp water solubility 5E+004 mg/L (at 25 °C) MERCK INDEX (1996) logP 1.39 SMITH,JT & VINJAMOORI,DT (1995) - Predicted Properties
Property Value Source Water Solubility 14.9 mg/mL ALOGPS logP 0.76 ALOGPS logP 0.34 Chemaxon logS -1.1 ALOGPS pKa (Strongest Acidic) 13.62 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 58.92 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 51.24 m3·mol-1 Chemaxon Polarizability 20.59 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9231 Blood Brain Barrier - 0.8631 Caco-2 permeable - 0.6755 P-glycoprotein substrate Substrate 0.5523 P-glycoprotein inhibitor I Non-inhibitor 0.7979 P-glycoprotein inhibitor II Non-inhibitor 0.9002 Renal organic cation transporter Non-inhibitor 0.88 CYP450 2C9 substrate Non-substrate 0.8348 CYP450 2D6 substrate Non-substrate 0.8535 CYP450 3A4 substrate Non-substrate 0.6853 CYP450 1A2 substrate Inhibitor 0.6013 CYP450 2C9 inhibitor Non-inhibitor 0.9592 CYP450 2D6 inhibitor Non-inhibitor 0.9616 CYP450 2C19 inhibitor Non-inhibitor 0.9328 CYP450 3A4 inhibitor Non-inhibitor 0.9481 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9445 Ames test Non AMES toxic 0.7677 Carcinogenicity Non-carcinogens 0.9215 Biodegradation Ready biodegradable 0.7769 Rat acute toxicity 2.0868 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9171 hERG inhibition (predictor II) Non-inhibitor 0.8735
Spectra
- Mass Spec (NIST)
- Download (7.98 KB)
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 150.6368923 predictedDarkChem Lite v0.1.0 [M-H]- 137.36125 predictedDeepCCS 1.0 (2019) [M-H]- 150.6368923 predictedDarkChem Lite v0.1.0 [M-H]- 137.36125 predictedDeepCCS 1.0 (2019) [M+H]+ 150.8847923 predictedDarkChem Lite v0.1.0 [M+H]+ 141.0494 predictedDeepCCS 1.0 (2019) [M+H]+ 150.8847923 predictedDarkChem Lite v0.1.0 [M+H]+ 141.0494 predictedDeepCCS 1.0 (2019) [M+Na]+ 149.8043923 predictedDarkChem Lite v0.1.0 [M+Na]+ 150.13516 predictedDeepCCS 1.0 (2019) [M+Na]+ 149.8043923 predictedDarkChem Lite v0.1.0 [M+Na]+ 150.13516 predictedDeepCCS 1.0 (2019)
Targets
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Voltage-gated cation channel activity
- Specific Function
- NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic p...
Components:
References
- Keshavarz M, Showraki A, Emamghoreishi M: Anticonvulsant Effect of Guaifenesin against Pentylenetetrazol-Induced Seizure in Mice. Iran J Med Sci. 2013 Jun;38(2):116-21. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55